PDF herunterladen
Open Access
CC BY 4.0 · Brazilian Journal of Oncology 2018; 14(50): 1-4
DOI: 10.5935/1806-6054.20190006
Editorial
Reviews

Year in Review 2018 - Breast Cancer Edition

Autoren

  • Gilberto Luiz da Silva Amorim

    1   Department of Medical Oncology, Oncologia D'Or Rio de Janeiro, RJ, Brazil

  • Debora Gagliato

    2   Beneficência Portuguesa Hospital, São Paulo, Brazil

  • Andrea Paiva Gadelha Guimaraes

    3   Department of Medical Oncology - AC Camargo Cancer Center, São Paulo, Brazil

  • Gustavo Nader Marta

    4   Department of Radiation Oncology, Sírio-Libanês Hospital, Department of Radiology and Oncology, São Paulo Cancer Institute (ICESP), Medicine Department São Paulo University, São Paulo, Brazil

  • Lisa Morikawa

    5   Department of Radiation Oncology, Oncologia D'Or, Rio de Janeiro, Brazil

  • Juliana Martins Pimenta

    2   Beneficência Portuguesa Hospital, São Paulo, Brazil

  • Solange Sanches

    3   Department of Medical Oncology - AC Camargo Cancer Center, São Paulo, Brazil

Financial support: none to declare.
Weitere Informationen
  Lizenzen und Reprints Alle Artikel dieser Rubrik

ABSTRACT

The Breast Cancer community witnessed the presentation of several important studies though 2018. From molecular evaluation of primary breast tissue to predict chemotherapy benefit, to major advances in systemic therapy in the metastatic setting, clinical trials highlighted in this BJO especial edition have truly major impact in current clinical practice for breast cancer patients.

RESUMO

A comunidade de câncer de mama testemunhou a apresentação de vários estudos importantes em 2018. Desde a avaliação molecular do tecido mamário primário para predizer o benefício da quimioterapia, até grandes avanços na terapia sistémica no cenário metastático. Os ensaios clínicos destacados nesta edição especial do BJO têm um impacto realmente importante na prática clínica atual para pacientes com câncer de mama.

Keywords:

Breast Neoplasms - Review - Combined Modality Therapy

Descritores:

Neoplasias da Mama - Revisão - Terapia de Modalidade Combinada


Publikationsverlauf

Eingereicht: 26. November 2018

Angenommen: 01. Februar 2019

Artikel online veröffentlicht:
11. März 2025

© 2022. This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • REFERENCES

  • Earl H, Hiller L, Vallier AL, Loi S, Howe D, Higgins H. et al PERSEPHONE Trial Investigators. PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. J Clin Oncol 2018; 36 (15_Suppl): 506
    CrossrefSuche in Google Scholar
  • Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N. et al Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016; 17 (04) 425-439
    CrossrefPubMedSuche in Google Scholar
  • Cristofanilli M, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M. et al Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor- positive (HR+), human epidermal growth factor receptor 2-negative (HER2_) advanced breast cancer (ABC): Analyses from PALOMA-3. Ann Oncol 2018; 29 (Suppl_8): mdy424.009
    Suche in Google Scholar
  • Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF. et al Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 2015; 373 (21) 2005-2014
    CrossrefPubMedSuche in Google Scholar
  • Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF. et al Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 2018; 379 (02) 111-121
    CrossrefPubMedSuche in Google Scholar
  • Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H. et al Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 2018; 379 (22) 210821
    Suche in Google Scholar
  • Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N. et al Olaparib for Metastatic Breast Cancer in Patients with a Germilne BRCA mutation. N Engl J Med 2017; 377 (06) 523-533
    CrossrefPubMedSuche in Google Scholar
  • Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH. et al Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med 2018; 379 (08) 753-763
    CrossrefPubMedSuche in Google Scholar
  • Smith BD, Bellon JR, Blitzblau R, Freedman G, Haffty B, Hahn C. et al Radiation therapy for the whole breast: Executive summary of American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol 2018; 8 (03) 145-152
    CrossrefPubMedSuche in Google Scholar
  • McCormick B. Randomized Trial Evaluating Radiation following Surgical Excision for “Good Risk” DCIS: 12-Year Report from NRG/ RTOG 9804. Int J Radiat Oncol Biol Phys 2018; 102 (05) 1603
    CrossrefSuche in Google Scholar